Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $120,984.98 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 7,459 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $120,984.98. Following the completion of the transaction, the chief executive officer owned 228,527 shares of the company’s stock, valued at $3,706,707.94. This trade represents a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Stock Performance

Personalis stock traded up $0.12 during midday trading on Tuesday, reaching $16.36. 1,369,078 shares of the stock were exchanged, compared to its average volume of 2,690,633. Personalis, Inc. has a 52 week low of $4.95 and a 52 week high of $18.89. The firm has a market cap of $1.71 billion, a PE ratio of -15.01 and a beta of 2.31. The company’s fifty day moving average is $15.06 and its 200-day moving average is $10.89.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. On average, sell-side analysts anticipate that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently made changes to their positions in the business. Tidal Investments LLC purchased a new stake in Personalis during the second quarter valued at about $1,146,000. WINTON GROUP Ltd purchased a new position in shares of Personalis in the second quarter worth about $496,000. Engineers Gate Manager LP bought a new stake in shares of Personalis in the 2nd quarter valued at about $1,552,000. Squarepoint Ops LLC purchased a new stake in Personalis during the 2nd quarter valued at about $319,000. Finally, Arizona State Retirement System boosted its holdings in Personalis by 28.2% during the 2nd quarter. Arizona State Retirement System now owns 18,766 shares of the company’s stock valued at $251,000 after acquiring an additional 4,131 shares during the period. Institutional investors own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Lake Street Capital downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, July 20th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. BTIG Research raised their price objective on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $14.54.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.